Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation

ClinicalTrials.gov ID: NCT03850509

Public ClinicalTrials.gov record NCT03850509. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Trial to Assess the Efficacy and Safety of Orally Administered OPS-2071 for 12 Weeks in Subjects With Crohn's Disease Showing Symptoms of Active Inflammation Despite Ongoing Treatment

Study identification

NCT ID
NCT03850509
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Enrollment
3 participants

Conditions and interventions

Interventions

  • OPS-2071 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 24, 2020
Primary completion
May 21, 2020
Completion
May 21, 2020
Last update posted
Jun 14, 2021

2020

United States locations

U.S. sites
24
U.S. states
12
U.S. cities
24
Facility City State ZIP Site status
United States, California Los Angeles California 90067
United States, California San Carlos California 94070
United States, Colorado Colorado Springs Colorado 80907
United States, Florida Clearwater Florida 33756
United States, Florida Hialeah Florida 33012
United States, Florida Kissimmee Florida 34759
United States, Florida Naples Florida 34102
United States, Florida Orlando Florida 32825
United States, Florida Plantation Florida 33322
United States, Georgia Decatur Georgia 30033
United States, Georgia Doraville Georgia 30362
United States, Kansas Shawnee Mission Kansas 66226
United States, Maryland Chevy Chase Maryland 20815
United States, North Carolina Greenville North Carolina 27834
United States, Ohio Cincinnati Ohio 45219
United States, Ohio Dayton Ohio 45417
United States, Oklahoma Oklahoma City Oklahoma 73112
United States, South Carolina Rock Hill South Carolina 29732
United States, Texas Austin Texas 78704
United States, Texas Harlingen Texas 78550
United States, Texas San Antonio Texas 78229
United States, Texas Sugar Land Texas 77479
United States, Texas Tyler Texas 75701
United States, Virginia Lynchburg Virginia 24502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03850509, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 14, 2021 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03850509 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →